EN DE
Watch Vuno Inc. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Vuno Inc. (338220) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Vuno Inc. stock KRW 1,690, price KRW 5,830, that is 71.0% below the price, quality 45 out of 100. Rating: strongly overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR

VI Vuno Inc. logo Thin data Nov 9, 2026

Vuno Inc.

338220 · KQ
Very expensive, weak quality

Our calculation puts a fair price 71% below what the stock costs today.

Low debt
Quality 45/100
Expensive Growth (revenue 5y +94.3 %/yr in KRW)
Revenue last quarter 34% below a year ago.
Fair value 1,690 KRW · Strongly overvalued
Loss-making · -36.6% net margin (TTM)
Negative free cash flow
Trails peers (0/10)
Narrow moat 8/100 · thin data
Thin data
Watch Vuno Inc. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

65,500 KRW 4,320 KRW Fair Value 1,690 KRW Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 9, 2026.

How to read this chart

60‑month range 4,320 KRW – 65,500 KRW · fair‑value band 1,115 KRW – 2,112 KRW · the 5,830 KRW price screens above the 1,690 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 9, 2026.

Follow Vuno in your weekly email

Every Wednesday you see whether Vuno is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Vuno Inc. engages in the artificial intelligence medical software development and services business. The company provides medical AI solutions for analyzing various medical data and assisting in disease diagnosis.

Show moreShow less

It also offers BoneAge, an AI diagnostic software for bone age assessment; DeepBrain, a brain parcellation for the quantitative analysis of neurodegenerative diseases and other neurological disorders; chest X-ray, a diagnostic support system for abnormalities in chest x-ray; fundus AI, an AI-based screening solution for various abnormalities in the fundus of the eye; DeepCARS, an AI-based cardiac arrest risk management system; and LungCT AI, an AI-based pulmonary lung nodule detection and reporting system.

In addition, the company provides medical products under HATIV brand, such as HATIV K30, a kiosk-type medical device that measures electrocardiograms; HATIV P30, a medical ECG device; HATIV BP30, an automatic blood pressure monitoring device; and HATIV TP50T, an ear infrared thermometer device.

The company was founded in 2014 and is headquartered in Seoul, South Korea.

Stock analysis

Vuno Inc. (338220) currently trades at 5,830 KRW, while our model-based Fair Value estimate is 1,690 KRW, 71% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the data coverage at low.

Scenario range: 1,115 KRW (bear) to 2,112 KRW (bull), the price of 5,830 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 45/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Vuno Inc. reported revenue of 34.8B KRW in FY2025 versus 2.2B KRW in FY2021, a compound +98.4%/yr. Reported net income was −5.8B KRW in FY2025.

Key figures

Market cap 81.6B KRW (≈ $60.4M) Micro · P/S ratio 3.27 · EPS (TTM) −789.02 KRW · Net margin −36.6% · Return on equity −35.5% · Return on assets (EBIT) −43.5% (5-year average) · Operating margin −68.9% · Revenue (TTM) 30.2B KRW.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).

What moves the price

The share trades about 79% below its 52-week high and 35% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 3% fair-value upside, at −71%, 338220 screens richer than that median.

Fair Value models

Bear 1,115 KRW Fair Value 1,690 KRW Bull 2,112 KRW
Price 5,830 KRW · Downside -71.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) 1,115 KRW 1,690 KRW 2,112 KRW 54
All 1 models by family
Asset-Based
NCAV (Graham) 1,115 KRW 1,690 KRW 2,112 KRW 54

Open the full fair value analysis →

Quality Score breakdown

Overall quality 45/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 29
How much profit the company makes from its sales and capital
Quality Growth 92
Are margins and returns getting better?
Cashflow 7
Do the profits arrive as real cash?
Financial strength 73
Debt, balance sheet and risk of trouble
Investment 44
Does it invest with discipline instead of growing at any price?
Low Volatility 33
How calm the share price moves, does not count
Price momentum 8
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 3
Distance to the 52-week high, does not count
New shares 39
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+34.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+61.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+94.3%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+95.7%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−773.3% (2020) → −14.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

338220 screens overvalued: fair value 71% below the price. Compare with Veeva Systems Inc →

Compare Vuno Inc. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Health Information Services · 117 stocks

Beats the industry median on 0/9 measures
Overall it trails its industry peers.
Valuation
Quality Score 45 · Below median
Fair Value upside −71.0% · Bottom 25%
Profitability
Return on assets −11.5% · Bottom 25%
Net margin (12 months) −36.6% · Bottom 25%
Operating margin (12 months) −68.9% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −34.0% · Bottom 25%
Balance sheet
Debt / equity 0.03× · Above median

Valuation Multiplesvs Health Information Services median · lower = cheaper

P/B 2.26× · Pricier than median
P/S (12 months) 2.70× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 5
FUTURE (revenue growth)0 · sector 46
PAST (return on equity)0 · sector 10
HEALTH (low debt)98 · sector 98
DIVIDEND (yield)0 · sector 41

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Health Information Services stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Veeva Systems Inc VEEV $303.73 $334.10 +10% vs 338220
HealthEquity, Inc HQY $103.63 $113.99 +10% vs 338220
Doximity, Inc DOCS $32.51 $35.76 +10% vs 338220
Inventurus Knowledge Solutions Limited IKS ₹1,657 ₹1,823 +10% vs 338220
Waystar Holding WAY $28.35 $29.10 +3% vs 338220
Hinge Health, Inc HNGE $115.76 $51.25 −56% vs 338220
Pro Medicus Limited PME A$205.49 A$85.12 −59% vs 338220
BrightSpring Health Services, Inc BTSG $67.15 $25.72 −62% vs 338220
XtalPi Holdings 2228 HK$6.13 HK$1.53 −75% vs 338220
Privia Health Group PRVA $24.42 $5.52 −77% vs 338220

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Vuno Inc.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Vuno Inc. Fair Value". https://www.fairvalue-calculator.com/stock/338220

Frequently asked questions

Is Vuno Inc. (338220) overvalued or undervalued?
As of Nov 9, 2026, our model estimates a fair value of 1,690 KRW versus a price of 5,830 KRW, about 71% lower (overvalued).
What is the fair value of 338220?
Our model-based fair value for Vuno Inc. is 1,690 KRW (as of Nov 9, 2026), built from audited fundamentals. The current price: 5,830 KRW.
What is the quality score of 338220?
Vuno Inc. has a Quality Score of 45/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Vuno Inc. (338220)?
Our model-based price target is the fair value of 1,690 KRW (as of Nov 9, 2026) from 1 valuation models. Cautious scenario 1,115 KRW, optimistic scenario 2,112 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Vuno Inc. stock forecast for 2026?
Our models put fair value at 1,690 KRW, about 71% lower versus a price of 5,830 KRW (overvalued). Cautious scenario 1,115 KRW, optimistic scenario 2,112 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Vuno Inc. (338220)?
Vuno Inc. reported trailing-twelve-month revenue of about 30.2B KRW (latest available figure, as of Nov 9, 2026).
What is the intrinsic value of Vuno Inc. (338220)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Vuno Inc. it is 1,690 KRW per share (as of Nov 9, 2026), against a price of 5,830 KRW. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Vuno Inc. stock overvalued or undervalued in 2026?
As of Nov 9, 2026, 338220 trades above its calculated fair value: price 5,830 KRW, fair value 1,690 KRW, a gap of about −71% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 338220?
No. The price is what the market pays today (5,830 KRW); the fair value is what the company's own numbers justify (1,690 KRW). For Vuno Inc. the two are 4,140 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Vuno Inc. worth?
The market values Vuno Inc. at about 81.6B KRW (market capitalisation, as of Nov 9, 2026). Per share that is 5,830 KRW; our models calculate a fair value of 1,690 KRW per share.
What do the bullish and bearish scenarios say about 338220?
Our models span a range for Vuno Inc.: cautious scenario 1,115 KRW, base 1,690 KRW, optimistic 2,112 KRW per share (as of Nov 9, 2026, price 5,830 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Vuno Inc. (338220)?
Balance-sheet figures for Vuno Inc. (as of Nov 9, 2026): return on equity −35.5%, debt of 0.03 per unit of equity. They feed the Quality Score of 45/100, which measures business quality independently of the share price.
How far is 338220 from its 52-week high?
Vuno Inc. trades at 5,830 KRW, about 79% below its 52-week high of 27,600 KRW and 35% above the low of 4,320 KRW (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 1,690 KRW is for.
Which stocks are comparable to Vuno Inc.?
From the same area (Healthcare) we also value Veeva Systems Inc, Pro Medicus Limited, BrightSpring Health Services, Inc, Hinge Health, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Vuno Inc. stock attractive at the current price?
The data as of Nov 9, 2026: price 5,830 KRW, calculated fair value 1,690 KRW (−71%), Quality Score 45/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 338220 calculated?
We run Vuno Inc. through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of 1,690 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Vuno Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Vuno Inc. (338220)?
The closing price on Nov 6, 2026 was 5,830 KRW. Our model-based fair value is 1,690 KRW, about 71% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Vuno Inc. right now?
The price sits above even our optimistic bull case (2,112 KRW). The favourable scenario is already priced in. Weak quality (45/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (1,115 KRW to 2,112 KRW) leaves room in how you read the outcome.

Key figures of Vuno Inc.

How large is the market capitalisation of Vuno Inc. (338220)?
The market capitalisation of Vuno Inc. is 81.6B KRW (≈ $60.4M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Vuno Inc. (338220)?
The price-to-sales ratio of Vuno Inc. is 3.27 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Vuno Inc. (338220)?
Earnings per share at Vuno Inc. are −789.02 KRW. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Vuno Inc. (338220)?
The net margin of Vuno Inc. is −36.6% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Vuno Inc. (338220)?
The return on equity (ROE) of Vuno Inc. is −35.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Vuno Inc. (338220)?
On an EBIT basis the return on assets of Vuno Inc. is −43.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Vuno Inc. (338220)?
The operating margin of Vuno Inc. is −68.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Vuno Inc. (338220)?
Revenue at Vuno Inc. is growing −34.0% versus a year earlier (3y avg +61.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Vuno Inc. (338220) generate?
The free cash flow of Vuno Inc. is −5.7B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Vuno Inc. (338220) carry?
The net debt of Vuno Inc. is 1.4B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Vuno Inc. in the live analysis

One click puts Vuno Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.